Clinical Trial Update: PAXIL CR Bioequivalence Study [Phase 1]

View source ↗

Summary

GlaxoSmithKline completed a Phase 1 bioequivalence study of Paxil CR (paroxetine controlled-release) for Depressive Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• Paxil CR (paroxetine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder | Phase 1 | Status: COMPLETED